Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828301 | 0.77 | CCR1 (0.36) | — | |
| SCHEMBL21969607 | 0.77 | MEN1 (0.42) | CYP3A4TSHR | |
| SCHEMBL12516223 | 0.77 | — | — | |
| SCHEMBL12892475 | 0.77 | CHRNB2 (0.33) | CYP3A4TSHRTDP2NSD2 | |
| SCHEMBL1483874 | 0.76 | CYP3A4 (0.38) | CYP3A4 | |
| SCHEMBL23375710 | 0.73 | MERTK (0.40) | CRHBPCRHR2TDP2NSD2 | |
| SCHEMBL12060293 | 0.73 | POLB (0.37) | TSHR | |
| SCHEMBL13761700 | 0.73 | — | — | |
| SCHEMBL17130981 | 0.71 | MEN1 (0.43) | — | |
| SCHEMBL21514409 | 0.71 | IKBKB (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11241428-B2 | Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2) | MEDIBIOFARMA, S.L. (ES) | 2022-02-08 | — | — | US | disclosed |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-13 | — | — | US | disclosed |
| WO-2020239855-A1 | MICROBIOCIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2020-12-03 | — | — | WO | disclosed |
| US-20200138808-A1 | NEW HETEROARYL AMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASES 1 AND/OR 2 (HDAC1-2) | MEDIBIOFARMA, S.L. (ES) | 2020-05-07 | — | — | US | disclosed |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-02-06 | — | — | US | disclosed |
| US-8110686-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKI KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-02-03 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7495009-B2 | Imidazopyridine derivatives as melancortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
| US-20080146536-A1 | 2-Aminoimidazopyridines for treating neurodegenerative diseases | PHARMACOPEIA, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | ME3, ME1, MLYCD | CYP3A4 251/4885TSHR 2736/4885CRHBP 4774/4885 |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | CYP3A4 160/4885TSHR 3792/4885CRHBP 2245/4885 |
| US-20080146536-A1 | 2-Aminoimidazopyridines for treating neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | CYP3A4 2941/4885TSHR 1079/4885CRHBP 2379/4885 |
| US-20200138808-A1 | NEW HETEROARYL AMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASES 1 AND/OR 2 (HDAC1-2) | HDAC1, HDAC2, HDAC11 | CYP3A4 3700/4885TSHR 3566/4885CRHBP 2839/4885 |
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | CYP3A4 3184/4885TSHR 2758/4885CRHBP 4459/4885 |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | CYP3A4 4000/4885TSHR 894/4885CRHBP 3765/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CYP3A4 2677/4885TSHR 1333/4885CRHBP 2211/4885 |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | IRAK4, IRAK1, IRAK2 | CYP3A4 3409/4885TSHR 3132/4885CRHBP 3313/4885 |
| US-11241428-B2 | Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2) | HDAC1, HDAC2, HDAC11 | CYP3A4 3445/4885TSHR 3750/4885CRHBP 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.